Tildrakizumab Market Report 2026

The tildrakizumab market size has grown rapidly in recent years. It will grow from $1.76 billion in 2025 to $1.96 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to increasing prevalence of plaque psoriasis, clinical validation of biologic efficacy, expansion of specialty dermatology clinics, growing acceptance of injectable biologics, availability of reimbursement support for biologics.

The tildrakizumab market size is expected to see rapid growth in the next few years. It will grow to $3.02 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing demand for personalized autoimmune therapies, expansion of biologic pipeline indications, rising focus on long-term disease management, growing adoption of home-based biologic administration, increasing investment in immunology research. Major trends in the forecast period include increasing use of targeted biologic therapies, rising adoption of il-23 inhibitors, growing preference for long-acting injectable treatments, expansion of specialty biologic distribution channels, enhanced focus on patient-centric treatment regimens.

The rising incidence of autoimmune diseases is expected to drive the growth of the tildrakizumab market in the coming years. Autoimmune diseases are conditions in which the immune system erroneously attacks the body’s own healthy tissues. The prevalence of autoimmune diseases is increasing due to environmental triggers such as pollution and chemical exposure. Tildrakizumab is used in autoimmune diseases by inhibiting the IL-23 pathway to reduce inflammation and manage symptoms. For example, in August 2024, data from Public Health Scotland, a Scotland-based national organization, reported that in 2023, the Scottish Multiple Sclerosis Register (SMSR) recorded 455 newly diagnosed MS patients. Therefore, the increasing incidence of autoimmune diseases is fostering the growth of the tildrakizumab market.

The enhancement of healthcare facilities is expected to support the growth of the tildrakizumab market in the coming years. Healthcare facilities are establishments that provide medical care and services, including hospitals, clinics, and diagnostic centers, to treat and support patients. Healthcare facilities are improving due to factors such as increased investments in healthcare infrastructure, emphasis on patient-centered care, population growth, and aging. Improving healthcare facilities enhances patient access to advanced biologic treatments, streamlines diagnosis and specialist referrals, ensures better cold chain management for biologics, and raises healthcare provider awareness, all of which collectively support the adoption and effectiveness of tildrakizumab in treating chronic inflammatory conditions like psoriasis. For example, according to the American Hospital Association, a US-based non-profit organization, in 2024, the United States had 6,120 hospitals, up from 6,093 hospitals in 2022. Therefore, the improvement of healthcare facilities is driving the growth of the tildrakizumab market.

Leading companies in the tildrakizumab market are focusing on the development of innovative formulations such as monoclonal antibody injections to enhance treatment effectiveness and improve patient outcomes. Monoclonal antibody injection refers to the administration of laboratory-produced antibodies designed to target specific antigens in the body for therapeutic or preventive purposes. For instance, in May 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, received approval from the Chinese health authority, National Medical Products Administration (NMPA), for tildrakizumab injection used in the treatment of plaque psoriasis. By targeting interleukin-23 (IL-23), a cytokine involved in the inflammatory response that causes psoriasis, tildrakizumab helps reduce inflammation and slow excessive skin cell growth, improving symptoms such as redness, scaling, and plaque formation.

Major companies operating in the tildrakizumab market are Almirall S.A., Sun Pharmaceutical Industries Ltd., Novartis, Pfizer, Eli Lilly, Bristol Myers Squibb, Roche, Merck & Co, Janssen Biotech (Johnson & Johnson), Amgen, GSK, AbbVie, Sanofi, AstraZeneca, Innovent Biologics, Boehringer Ingelheim, LEO Pharma, Kyowa Kirin, Takeda Pharmaceutical, Regeneron Pharmaceuticals, Biocon Ltd.

North America was the largest region in the tildrakizumab market in 2025. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in the tildrakizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tildrakizumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the tildrakizumab market by increasing costs of imported biologic raw materials, monoclonal antibody manufacturing inputs, cold-chain packaging, and sterile injectable components. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on cross-border biologic supply chains, while Asia-Pacific faces higher production and distribution costs. These tariffs are influencing treatment pricing and reimbursement negotiations. However, they are also driving regional biologics manufacturing, local fill-and-finish investments, and supply chain localization to enhance long-term drug availability.

The tildrakizumab market research report is one of a series of new reports that provides tildrakizumab market statistics, including tildrakizumab industry global market size, regional shares, competitors with a tildrakizumab market share, detailed tildrakizumab market segments, market trends and opportunities, and any further data you may need to thrive in the tildrakizumab industry. This tildrakizumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tildrakizumab is a humanized monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), inhibiting its binding to the IL-23 receptor. By blocking this interaction, it prevents downstream inflammatory signaling, thereby reducing the activation of pro-inflammatory cytokines and immune cells involved in autoimmune disorders such as plaque psoriasis.

The primary uses of tildrakizumab include plaque psoriasis, psoriatic arthritis, and other related conditions. Plaque psoriasis is a long-term autoimmune skin disorder characterized by inflamed, scaly patches of skin called plaques. The medication is available in both injectable and oral formulations and is supplied through hospital pharmacies, retail pharmacies, and online pharmacies. It is utilized by a range of end users, including hospitals, specialty clinics, and home care settings.

The tildrakizumab market consists of sales of single-dose vials and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.